Page 2 - நெப்ராலஜி மற்றும் சிறுநீரகம் சாதனங்கள் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from நெப்ராலஜி மற்றும் சிறுநீரகம் சாதனங்கள். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In நெப்ராலஜி மற்றும் சிறுநீரகம் சாதனங்கள் Today - Breaking & Trending Today

Paul Pepper: Dr. Smrita Dorairajan, Truman Veterans' Hospital, "Obesity and Your Kidneys"


Smrita Dorairajan, MD
What happens to our kidneys if we re overweight, obese or morbidly obese? The answer is two-fold, according to DR. SMRITA DORAIRAJAN, nephrology specialist at Truman Veterans Hospital. Directly-speaking, it means your kidneys have to work overtime to clear out the body s toxins; indirectly-speaking, it means your kidneys are on clean-up duty from any number of problems that may occur from having a high BMI. March 4, 2021
Tags:  ....

Truman Veteran , Smrita Dorairajan , Truman Veterans 039 Hospital , Paul Pepper , Radio Friends , ட்ரூமன் மூத்த , பால் மிளகு , வானொலி நண்பர்கள் ,

Nephrology And Urology Devices Global Market Report 2021: COVID 19 Impact and Recovery to 2030

Major companies in the nephrology and urology devices market include Baxter International Inc; Fresenius Medical Care AG & Co KGaA; Cook Group Incorporated; B. Braun Group and C. R. Bard Inc.New York, Feb. 24, 2021 (GLOBE NEWSWIRE) Reportlinker.com announces the release of the report "Nephrology And Urology Devices Global Market Report 2021: COVID 19 Impact and Recovery to 2030" - https://www.reportlinker.com/p06027750/?utm source=GNW The global nephrology and urology devices market is expected to grow from $23.45 billion in 2020 to $25.67 billion in 2021 at a compound annual growth rate (CAGR) of 9.5%. The growth is mainly due to the companies rearranging their operations and recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The market is expected to reach $31.87 billion in 2025 at a CAGR of 6%.The ....

Baxter International Inc , Cook Group Incorporated , Treatment Devices , Compound Annual Growth Rate , பாக்ஸ்டர் சர்வதேச இன்க் , சமைக்கவும் குழு இணைக்கப்பட்டது , சிகிச்சை சாதனங்கள் , கலவை ஆண்டு வளர்ச்சி ரேட் ,

Psychosocial factors may contribute to dropout of patients from peritoneal dialysis


Psychosocial factors may contribute to dropout of patients from peritoneal dialysis
A retrospective study conducted by LSU Health New Orleans reports that contrary to previous research, most patients who drop out of peritoneal dialysis may do so for psychosocial reasons. The findings are published in
The American Journal of the Medical Sciences.
The research team evaluated the reasons that 27 of the 83 patients enrolled in the peritoneal dialysis program withdrew between 2016 and 2018. Twenty-four or 86% were African American. They found that psychosocial factors, including mental health illness such as anxiety and depression, loss of support networks, or inability to tolerate the number of treatment sessions required by peritoneal dialysis, accounted for 63% of the dropout rate due to controllable factors. ....

United States , Sreedhar Mandayam , Hayden Torres , Biruht Workeneh , Emily Henderson , National Institutes Of Health , Md Anderson Cancer Center , Department Of Nephrology , American Journal Of The Medical Sciences , Health New Orleans , Health New Orleans School Of Medicine , University Of Texas , New Orleans , American Journal , National Institutes , African American , Native Americans , New Orleans School , Cancer Center , Kidney Disease , Kidney Failure , Mental Health , Renal Disease , ஒன்றுபட்டது மாநிலங்களில் , ஹைடன் டோரஸ் , எமிலி ஹென்டர்சன் ,

Granules India receives USFDA approval for Potassium Chloride ER Capsules


Granules India announced that the US Food & Drug Administration (US FDA) has approved its
Abbreviated New Drug Application (ANDA) for Potassium Chloride Extended-Release Capsules USP, 8 mEq
(600 mg) and 10 mEq (750 mg). It is bioequivalent to the reference listed drug product (RLD), Micro-K
Extended-Release Capsules, 8 mEq and 10 mEq, of Nesher Pharmaceuticals (USA) LLC.
The product would
be manufactured at the company s Hyderabad facility and is expected to be launched shortly.
Potassium Chloride is indicated for the treatment of patients with hypokalemia with or without metabolic
alkalosis, in digitalis intoxications, and in patients with hypokalemic familial periodic paralysis. It is also
indicated for the prevention of hypokalemia in patients who would be at particular risk if hypokalemia ....

Andhra Pradesh , Nesher Pharmaceuticals United States , Us Food Drug Administration , Granules India , Drug Administration , Abbreviated New Drug Application , Potassium Chloride Extended Release Capsules , Microk Extended Release Capsules , Nesher Pharmaceuticals , United States , Capital Market , Medical Specialties , Physical Sciences , Electrolyte Disturbances , Dietary Minerals , Metabolic Alkalosis , Potassium Chloride , Significant Cardiac Arrhythmias , ஆந்திரா பிரதேஷ் , ணேஷேற் மருந்துகள் ஒன்றுபட்டது மாநிலங்களில் , துகள்கள் இந்தியா , படாஸீயம் குளோரைடு நீட்டிக்கப்பட்டது வெளியீடு காப்ஸ்யூல்கள் , ணேஷேற் மருந்துகள் , ஒன்றுபட்டது மாநிலங்களில் , மூலதனம் சந்தை , மருத்துவ சிறப்பு ,